Investor Presentaiton

Revenue Increased by 70.5 Bn JPY (Increased by 59.0 Bn JPY excl. forex impact) FY2022 Q1 Results Japan Business (incl. Innovative Pharmaceuticals, Generic, Vaccines, OTC) Oncology Business*1 American Regent EU Specialty Business ASCA (Asia, South and Central America) Enhertu, Dato-DXd*2 Upfront/Quid Payment & Regulatory/Sales Milestone Forex Impact*3 FY2023 Q1 Results Daiichi-Sankyo (Bn JPY) Positive Factors Negative Factors 280.3 12.2 *39.1 Japan Business Unit Lixiana +2.8 Tarlige +2.8 Enhertu +1.9 Efient +1.3 Daiichi Sankyo Healthcare +1.9 0.8 Oncology Business *1 Unit Enhertu +38.7 1.2 American Regent Unit 6.9 Venofer +2.5 Injectafer -1.7 1.2 | EU Specialty Business Unit Lixiana 11.5 Nilemdo/ Nustendi +1.2 +1.5 Olmesartan -1.0 350.8 ASCA (Asia, South and Central America) Business Unit Positive Factors Negative Factors Enhertu +5.5 *1 Revenue for Daiichi Sankyo, Inc. and Daiichi Sankyo Europe's oncology products *2 Dato-DXd: Datopotamab deruxtecan (DS-1062) *3 Forex impact USD: +6.4, EUR: +4.5, ASCA: +0.7 5

View entire presentation